Antiemetic Therapy
Customize your policy alerts
Sign up for Aetna Policy 0724 alerts
Get alerted when Policy 0724 changes without checking for updates manually.
Monitor payer policy activity
Clinical policy governing intravenous and selected injectable antiemetic therapies for prevention and treatment of nausea and vomiting related to cancer chemotherapy, radiotherapy, postoperative settings, pregnancy, and other refractory indications; applicable to Aetna-covered members and providers submitting claims for these interventions.
No material clinical or coverage changes in this revision.
Coverage Criteria for Antiemetic Therapy
inv-01: Cancer chemotherapy — primary prophylaxis and treatment
Covered when the following criteria are met for the specified agents and indications
inv-02: Radiotherapy and post-operative indications
Covered when listed conditions and prior therapy failures/contraindications apply
Routine prophylaxis is not recommended when expectation of PONV is low.
inv-03: Pregnancy — severe intractable nausea and vomiting
Covered when ALL of the following are met
When these conditions are met, IV granisetron or ondansetron are covered; IV palonosetron, dolasetron or fosaprepitant are options when IV granisetron or ondansetron at FDA dose have failed or are contraindicated.
inv-04: Experimental / Investigational
Interventions considered experimental/investigational (not covered) due to insufficient evidence
FDA safety concerns for IV dolasetron include QT prolongation and risk of torsade de pointes.
inv-05: Other indications — refractory non-oncology
Covered when prior failures/contraindications to oral agents documented
inv-06: Guideline-based coverage criteria for antiemetic prophylaxis
Covered when regimens align with emetogenic risk and guideline-recommended agents/dosing
References: NCCN; Emend prescribing information
Palonosetron preferred for delayed emesis
MASCC/NCCN radiotherapy guidance
Aloxi labeling and anesthesia society consensus
inv-07: Coverage for NK1-containing antiemetic regimens
Covered when ALL of the following are met
Document emetogenicity of chemotherapy and regimen components per prescribing information
NCCN supports adding NK1 for select high-risk patients or prior failure of steroid+5-HT3
Ensure availability of follow-on oral doses when required (eg, 115 mg fosaprepitant requires confirmed access to Day 2 and 3 oral doses)
inv-08: Coverage for 5-HT3 receptor antagonists
Covered when ALL of the following are met
Dolasetron injection should not be administered for prevention of CINV due to QT prolongation and torsades risk; tablet formulation may be considered with caution.
inv-09: Aprepitant — gastroparesis evidence
Evidence summary for aprepitant in gastroparesis
Secondary outcomes showed improvement for some symptom measures; adverse events were more common with aprepitant (35% vs 17%).
inv-10: NEPA (Akynzeo) — CINV
NEPA (netupitant/fosnetupitant + palonosetron) IV and oral safety and effectiveness
Akynzeo injection is FDA-approved in combination with dexamethasone for prevention of acute and delayed nausea and vomiting with highly emetogenic chemotherapy; not studied for AC regimens in initial approval.
inv-11: Aromatherapy — PONV
Aromatherapy for PONV and isopropyl alcohol comparisons
Overall evidence quality ranged low to very low; findings are uncertain.
inv-12: DEX-sparing regimens with NEPA
DEX-sparing NEPA regimens in older patients fit for cisplatin
Subset included 107 patients >65 years; outcomes similar across DEX regimens.
inv-13: Palonosetron — PDNV
Palonosetron for post-discharge nausea and vomiting (PDNV)
The policy lists specific ICD-10 codes that are not considered covered indications under this Clinical Policy Bulletin. Notably, K31.84 (gastroparesis) and the range T75.3xxA–T75.3xxS (motion sickness) are identified as ICD-10 codes not covered for the indications described in this CPB. Additionally, intravenous dolasetron (Anzemet) for prevention of chemotherapy-induced nausea and vomiting is described as experimental/investigational and therefore not supported for that indication.
Safety considerations in the policy highlight that the intravenous formulation of dolasetron (Anzemet) should not be used to prevent chemotherapy-induced nausea and vomiting because of an increased risk of torsades de pointes and other serious cardiac arrhythmias; this injectable formulation is contraindicated for CINV per the FDA. The policy further emphasizes that fosaprepitant (Emend IV) is indicated only for prevention of CINV in patients receiving concurrent moderate- to highly-emetogenic chemotherapy, is not intended as monotherapy, and has specific contraindications and drug-interaction cautions (e.g., medications metabolized by CYP3A4).
Emend (fosaprepitant/aprepitant) is indicated for prevention of chemotherapy-induced nausea and vomiting only when administered as part of a multi-drug prophylactic regimen for patients receiving concurrent moderate- to highly-emetogenic chemotherapy. Emend IV is not indicated for patients who are not receiving concurrent moderate-to-high emetogenic chemotherapy and should not be used as monotherapy; dosing and use should follow the product labeling and ASCO/NCCN guidance.
Akynzeo injection (fosnetupitant/palonosetron) is FDA-approved in combination with dexamethasone for prevention of acute and delayed nausea and vomiting with highly emetogenic chemotherapy. The product labeling and the policy note that Akynzeo for injection has not been studied for prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide (AC) regimens, and thus effectiveness and safety for that specific regimen have not been established.
The appendix included with the policy provides an evidence-based classification of antineoplastic agents by their emetogenic potential (high, moderate, low, minimal) to guide selection of prophylactic antiemetic regimens. This appendix is informational in nature and, in the excerpt provided, does not state explicit coverage exclusions; it is intended to assist clinicians in matching antiemetic prophylaxis to the emetogenic risk of specific cancer therapies.
Administrative information and external links are provided for convenience; the document makes clear that Aetna is not responsible for the content, accuracy, or privacy practices of linked non-Aetna sites. Clinical Policy Bulletins offer summary guidance and do not themselves guarantee coverage; providers should consult the main clinical policy and plan documents for complete benefit and authorization details.
The policy states that routine prophylaxis is not recommended for individuals who have little expectation of postoperative nausea and/or vomiting; prophylactic therapy should be targeted to patients with an anticipated risk or those meeting established clinical indications.
Evidence does not support routine repeat dosing of palonosetron (Aloxi) on Days 2–3 following a single-day chemotherapy exposure, nor is routine repeat dosing established for many multi-day chemotherapy regimens. Palonosetron is approved as a single IV dose (0.25 mg) prior to chemotherapy and the need for additional doses in the subsequent days has not been demonstrated to improve outcomes.
Anzemet (dolasetron) injection carries a known risk of QT interval prolongation and torsades de pointes and therefore should not be administered for prevention of CINV; the oral tablet formulation may be considered in certain situations but retains an increased cardiac risk profile. This safety concern led to regulatory guidance restricting the use of intravenous dolasetron for CINV.
Use of aprepitant for gastroparesis is not supported by the primary randomized trial outcome: the randomized study cited did not demonstrate a statistically significant reduction in nausea severity on the primary VAS outcome. Secondary symptom measures showed some benefit, but overall the trial results and subsequent reviews indicate that routine use of aprepitant for gastroparesis remains unsupported by high-quality randomized evidence.
Coding and Emetogenic Classification
| C9145 | Injection, aprepitant, (aponvie), 1 mg |
| J0185 | Injection, aprepitant, 1 mg |
| J1260 | Injection, dolasetron mesylate, 10 mg |
| J1453 | Injection, fosaprepitant, 1 mg |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg |
| J1456 | Injection, fosaprepitant (teva), not therapeutically equivalent to J1453, 1 mg |
| J1626 | Injection, granisetron HCl, 100 mcg |
| J2405 | Injection, ondansetron HCl, per 1 mg |
| J2469 | Injection, palonosetron HCl, 25 mcg |
| J2797 | Injection, rolapitant, 0.5 mg |
| Q0162 | Ondansetron 1 mg, oral, FDA-approved presecription anti-emetic, for use as a complete therapeutic substitute for an IV anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
| Q0166 | Granisetron HCl, 1 mg, oral, FDA approved prescription anti-emetic, for use as a complete therapeutic substitute for an IV anti-emetic at the time of chemotherapy treatment, not to exceed a 24-hour dosage regimen |
| Q0180 | Dolasetron mesylate, 100 mg, oral, FDA approved prescription anti-emetic, for use as a complete therapeutic substitute for an IV anti-emetic at the time of chemotherapy treatment, not to exceed a 24-hour dosage regimen |
| B20 | Human immunodeficiency virus [HIV] disease |
| F50.2 | Bulimia nervosa |
| O21.0 - O21.9 | Excessive vomiting in pregnancy [when clinical signs of dehydration are present or nausea and vomiting have persisted more than 3 weeks and criteria A,B, and C are met] |
| R11.0 | Nausea |
| R11.10 - R11.14 | Vomiting |
| T66.xxx+ | Radiation sickness, unspecified [nausea or vomiting secondary to total body irradiation] |
| Z51.0 | Encounter for antineoplastic radiation therapy [for total body radiation when oral antiemetic therapy has failed or is contraindicated] |
| Z51.11 - Z51.12 | Encounter for antineoplastic chemotherapy and immunotherapy [for total body radiation when oral antiemetic therapy has failed or is contraindicated] |
| K31.84 | Gastroparesis |
| T75.3xxA - T75.3xxS | Motion sickness |
| R11.11 | Vomiting without nausea |
| R11.12 | Projectile vomiting |
| R11.2 | Nausea with vomiting, unspecified |
| T45.1X5+ | Adverse effect of antineoplastic and immunosuppressive drugs [not covered for Anzemet] |
| T66.xxx+ | Radiation sickness, unspecified |
| Z51.0 | Encounter for antineoplastic radiation therapy |
| Z51.11 | Encounter for antineoplastic chemotherapy |
| Z51.12 | Encounter for antineoplastic immunotherapy |
| K31.84 | Gastroparesis |
| T75.3xxA - T75.3xxS | Motion sickness |
| No codes listed |
Provider Actions, Prior Authorization and Documentation
Prior Authorization Required for Injectable Antiemetics
Prior authorization required for injectable antiemetics when billing the listed HCPCS/J-codes (e.g., J0185, J1260, J1453, J1454, J1456, J1626, J2405, J2469, J2797, J2469). Coverage is contingent on meeting the clinical criteria in this policy (emetogenic risk, prior therapy failures, or pregnancy exceptions).
Prior Authorization for NK1 Antagonists
Prior authorization required for NK1 receptor antagonists (e.g., fosaprepitant/Emend, aprepitant/Cinvanti, rolapitant/Varubi) — IV NK1 agents are indicated only in combination with a 5‑HT3 antagonist and dexamethasone and only for prevention of CINV in patients receiving moderate-to-high emetogenic chemotherapy.
- NK1 agents must be used as part of a multi-drug antiemetic regimen (NK1 + 5‑HT3 antagonist + dexamethasone)
- Emend IV (fosaprepitant) not indicated as monotherapy or without concurrent moderate-to-high emetogenic chemotherapy
PA Required for NK1 Agents in Multi‑drug CINV Prophylaxis
When requesting NK1 agents for CINV prophylaxis, prior authorization should document that use is part of a multi‑drug regimen (NK1 + 5‑HT3 antagonist + dexamethasone) and corresponds to the emetogenicity-based regimen (moderate or high). Prior authorization should not be approved for NK1 monotherapy or for indications outside prevention with concurrent moderate‑to‑high emetogenic chemotherapy.
- Document regimen components and timing (Day 1 IV dose and planned oral follow-on doses when applicable)
- Emend 115 mg IV requires confirmed access to Day 2 and Day 3 oral aprepitant before initiating IV Day 1 dose
Prior Authorization for Antiemetic Agents
Prior authorization expectations for antiemetic agents: submit clinical indication, emetogenic risk of the chemotherapy or reason for IV use (e.g., failed or contraindicated oral therapy, severe pregnancy with dehydration), prior medication trials, and planned regimen details (drug names, doses, schedule).
- Include emetogenicity classification of chemotherapy agent/regimen (appendix/NCCN)
- If for pregnancy, include duration (>3 weeks), dehydration signs, and failure of conservative and oral therapies
Use of Intravenous Dolasetron (Anzemet)
Intravenous dolasetron (Anzemet) is not covered for prevention of nausea and vomiting from cancer chemotherapy and is considered experimental/investigational for this indication due to safety concerns.
- HCPCS: J1260 (injection, dolasetron) noted in code list but IV dolasetron for CINV is considered experimental/not covered per policy
- FDA safety warning: IV dolasetron increases risk of torsades de pointes
Dolasetron IV Safety — Not Covered for CINV
IV dolasetron mesylate carries a documented safety risk (QT prolongation/torsades). The FDA recommends it should not be used to prevent CINV in pediatric and adult patients; therefore IV dolasetron is contraindicated for CINV prophylaxis and will not meet medical necessity.
- Documented FDA advisory: increased risk of fatal arrhythmia (torsades de pointes)
- IV dolasetron for CINV is listed as experimental/investigational and not medically necessary
Contraindications and Required Access to Follow‑on Oral Doses
For NK1 IV agents with multi-day oral follow-on therapy (e.g., Emend 115 mg IV followed by oral aprepitant), ensure the member has confirmed access to Day 2 and Day 3 oral doses prior to authorizing the Day 1 IV dose; contraindications (pimozide, terfenadine, astemizole, cisapride) and hypersensitivity to components (polysorbate 80) must be assessed.
- Confirmed access to Day 2/3 oral aprepitant required for 115 mg IV Emend
- Do not use in patients on pimozide, terfenadine, astemizole, cisapride, or with hypersensitivity to product components
No Explicit Prior Authorization or Billing Denial Triggers Specified
This policy excerpt does not specify a universal list of administrative prior‑authorization triggers or automated billing denial rules; consult the payer's main Clinical Policy Bulletin or benefits/contracts for specific PA process, required forms, and billing denial triggers.
- No explicit PA workflow or automated denial triggers are described in this section
- Providers should verify plan-specific prior authorization procedures before billing
No Denial Triggers Specified in These Sections; Clinical Exclusions Apply
The excerpt does not list specific denial triggers tied solely to the clinical content beyond the drug-specific exclusions (e.g., IV dolasetron not covered, NK1 without appropriate regimen). Use of agents outside listed indications or without required documentation may result in denial.
- Denials likely when IV agents are used outside FDA‑approved indications or policy criteria (e.g., NK1 monotherapy, IV dolasetron for CINV)
- Provide full documentation to avoid denial
Pregnancy IV Antiemetic Documentation
Pregnancy: documentation required for IV antiemetic use — severe, intractable, persistent nausea/vomiting with clinical signs of dehydration or symptoms >3 weeks, failure of conservative measures, failure/contraindication to oral/sublingual/rectal agents (≥2 agents), and failure/contraindication to other injectable agents (all listed).
- List prior conservative treatments tried (dietary changes, ginger, vitamin B6, doxylamine)
- Document trials/failures of ≥2 oral antiemetics and failure/contraindication to injectable agents
Indication and Dosing Documentation
Indication and dosing documentation should support the specific clinical scenario: emetogenicity of chemotherapy (moderate/high), dose and timing per product labeling (e.g., palonosetron 0.25 mg IV 30 minutes prior to chemotherapy; fosaprepitant 150 mg IV 30 minutes prior in combination regimens), and planned adjunctive corticosteroid and 5‑HT3 agent.
- Document product dosing and timing per prescribing information (Aloxi, Emend, Cinvanti, Akynzeo)
- For Emend/fosaprepitant, document combination with dexamethasone and a 5‑HT3 antagonist
Regimen and Emetogenicity Documentation
Regimen and emetogenicity documentation: prior authorization requests must show the chemotherapy emetogenic risk and that the antiemetic regimen follows NCCN-based sequencing (e.g., add NK1 for high-risk or select moderate-risk patients, palonosetron preferred for moderate risk). Escalation to an NK1 agent should be documented for patients with inadequate control on steroid + 5‑HT3 antagonist or with additional risk factors.
- State prior antiemetic regimens and clinical response (inadequate control warrants NK1 addition)
- Reference NCCN emetogenicity classification and rationale for escalation
Akynzeo Injection Prescribing Note
Akynzeo injection (fosnetupitant/palonosetron) is FDA‑approved for prevention of acute and delayed nausea and vomiting with highly emetogenic chemotherapy in combination with dexamethasone; include this prescribing-note when requesting coverage for Akynzeo IV.
- Akynzeo injection indicated in adults in combination with dexamethasone for HEC
- Not studied for anthracycline plus cyclophosphamide regimens per labeling
Documentation Note — CPB Scope
Documentation note: Clinical Policy Bulletins summarize plan benefits and clinical criteria but do not guarantee coverage. Providers remain responsible for submitting complete clinical documentation to support medical necessity and must confirm member benefits and PA requirements with the plan.
- CPBs are a partial description of benefits and not a contract or guarantee of coverage
- Confirm member-specific benefits and authorization procedures prior to treatment
Step Therapy — Informational
No step‑therapy mandates are specified in this excerpt. The policy describes stepwise/sequence-based clinical approaches (e.g., IV palonosetron or fosaprepitant allowed for prevention; dexamethasone‑sparing NEPA options) but does not impose administrative step‑therapy or prior trials beyond the clinical criteria already listed.
- Informational only: describes clinical sequencing and DEX‑sparing regimens (NEPA)
- Providers should follow clinical criteria; check payer for any separate step‑therapy programs
Emetogenic Risk‑Based Regimen Sequencing
Emetogenic risk‑based regimen sequencing: antiemetic regimens should follow emetogenic risk stratification (minimal, low, moderate, high) consistent with NCCN guidance — e.g., NK1 + 5‑HT3 + dexamethasone for high risk; palonosetron preferred for moderate risk; no routine prophylaxis for minimal risk.
- Specify the emetogenicity classification of the chemotherapy when requesting prophylactic IV antiemetics
- Use NCCN guidance to justify regimen selection (appendix lists agents by emetogenic potential)
Escalation to NK1 Agent After Inadequate Control or High‑Risk Scenarios
Escalation to an NK1 agent: add an NK1 (aprepitant/fosaprepitant/rolapitant) to dexamethasone + 5‑HT3 antagonist for select patients who have inadequate control with steroid + 5‑HT3 or who have additional risk factors (e.g., regimens such as carboplatin, cyclophosphamide, doxorubicin, epirubicin, ifosfamide, irinotecan, methotrexate). Document prior therapy failure and rationale for escalation.
- Document prior steroid + 5‑HT3 use and inadequate response
- List specific risk factors or high‑emetic‑risk agents prompting NK1 addition
Background and Definitions
5-HT3 receptor antagonists (including palonosetron, dolasetron, granisetron, and ondansetron) act by blocking serotonin at vagal afferents and central emesis pathways and are used to prevent and treat postoperative and therapy-related nausea and vomiting. Palonosetron is a second-generation 5-HT3 antagonist with a longer half-life and demonstrated efficacy for both acute and delayed chemotherapy-induced nausea and vomiting.
Recommended and Covered Antiemetic Regimens
inv-62: first-line — top-level node for first-line regimens (CINV prophylaxis context)
inv-63: first-line — single top-level node (CINV prophylaxis)
inv-64: first-line — top-level node describing initial regimen choices
Per NCCN and Emend labeling
inv-65: first-line — first-line node emphasizing NK1 agent addition when indicated
inv-66: informational — NEPA/DEX-sparing trial outcomes and context
Informational; relates to Akynzeo approval and trial outcomes.
| Regimen | Indication / Notes |
|---|---|
| Aprepitant + dexamethasone + 5-HT3 antagonist (with/without lorazepam) | Prophylaxis for highly emetogenic chemotherapy; recommended by NCCN as the antiemetic regimen for highly emetogenic drugs. |
| Combined palonosetron and fosaprepitant | Option for individuals with high emetic risk who have failed prior steroid plus 5-HT3 antagonist therapy. |
| Regimen | Indication / Notes |
|---|---|
| Dexamethasone + 5-HT3 antagonist (palonosetron preferred) | Recommended prophylaxis for moderately emetogenic chemotherapy; consider adding aprepitant for selected agents (eg, carboplatin). |
| Agent / Dosing | Administration / Notes |
|---|---|
| Fosaprepitant 150 mg IV (Day 1) | Administer IV over 20–30 minutes ~30 minutes prior to chemotherapy in combination with dexamethasone and a 5‑HT3 antagonist for moderately and highly emetogenic regimens per prescribing information. |
| Fosaprepitant 115 mg IV (Day 1) | Used for certain regimens (MEC/HEC) as specified; when 115 mg is used, protocol includes follow-on oral aprepitant on Days 2–3—ensure availability of oral doses. |
| Aprepitant (Cinvanti) IV 130 mg single dose (HEC) | IV single-dose regimen for highly emetogenic chemotherapy: 130 mg on Day 1 as an infusion ~30 minutes prior to chemotherapy, given with dexamethasone and a 5‑HT3 antagonist. |
| Aprepitant (Cinvanti) IV 100 mg single dose (MEC) + oral Days 2–3 | Moderately emetogenic chemotherapy regimen: 100 mg IV on Day 1 with oral aprepitant (80 mg) on Days 2 and 3, plus dexamethasone and a 5‑HT3 antagonist per product labeling. |
| Rolapitant oral 180 mg single dose | Oral rolapitant 180 mg given as single dose in combination with a 5‑HT3 antagonist and dexamethasone for prevention of delayed CINV. |
| Rolapitant IV 166.5 mg infusion | IV rolapitant (ready-to-use emulsion) administered as single infusion in combination with a 5‑HT3 antagonist and dexamethasone per product information. |
| Product / Dose | Indication / Timing |
|---|---|
| Palonosetron (Aloxi) 0.25 mg IV single dose | Prophylaxis for acute and delayed chemotherapy-induced nausea and vomiting; administer as a single 0.25 mg IV dose ~30 minutes prior to chemotherapy. |
| Palonosetron (Aloxi) 0.075 mg IV single dose | Prophylaxis for postoperative nausea and vomiting (PONV); administer 0.075 mg IV immediately before induction of anesthesia (effective up to 24 hours). |
| Agent | Dosing / Combination Use |
|---|---|
| Fosaprepitant (Emend) | Available as IV 115 mg or 150 mg doses for Day 1 administration; used in combination with dexamethasone and a 5‑HT3 antagonist for prevention of acute and delayed CINV per prescribing information. |
| Aprepitant (Cinvanti) | IV single-dose regimens: 130 mg on Day 1 for HEC; 100 mg on Day 1 for MEC with oral aprepitant (80 mg) on Days 2–3 as specified; used with dexamethasone and a 5‑HT3 antagonist. |
| Rolapitant (Varubi) | Available as oral 180 mg single dose or IV 166.5 mg infusion; given in combination with a 5‑HT3 antagonist and dexamethasone for prevention of delayed CINV. |
| Regimen | Outcome / Notes |
|---|---|
| NEPA (netupitant/palonosetron) + single-dose dexamethasone (DEX1) | DEX-sparing regimen evaluated in older patients fit for cisplatin; single-dose DEX with NEPA produced similar complete response rates and patient-reported outcomes compared with standard multi-day dexamethasone. |
| NEPA + short-course low-dose dexamethasone (DEX3) | Short-course low-dose dexamethasone (days 2–3) with NEPA also showed non-inferior effectiveness versus standard multi-day DEX in the cited subset analyses. |
| Emetogenic Category | Examples / Source |
|---|---|
| High (greater than 90% frequency of emesis) | Examples listed in Appendix (eg, cisplatin ≥50 mg/m2, AC combination, dacarbazine); source: NCCN, 2019. |
| Moderate (30–90% frequency of emesis) | Appendix provides multiple agents classified as moderate risk (eg, carboplatin, oxaliplatin); source: NCCN, 2019. |
| Low (10–30% frequency of emesis) | Appendix lists many agents categorized as low risk; source: NCCN, 2019. |
| Minimal (less than 10% frequency of emesis) | Appendix lists agents considered minimal-risk (see minimal-risk table); source: NCCN, 2019. |
| Minimal-risk Agents | Notes / Source |
|---|---|
| Agents considered minimal-risk (examples) | Appendix lists multiple agents considered minimal-risk (eg, alemtuzumab, asparaginase, atezolizumab, avelumab, bevacizumab, bleomycin, etc.); classification from NCCN 2019. |
Line of Therapy Considerations
inv-62: first-line — 1 top-level node
inv-63: first-line — 1 top-level node
inv-64: first-line — 1 top-level node
Per NCCN and Emend labeling
inv-65: first-line — 1 top-level node
inv-66: informational — 1 top-level node (NEPA program context)
Informational context for regimen selection.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.